Latest News and Press Releases
Want to stay updated on the latest news?
-
Anteris DurAVR THV demonstrates favorable hemodynamics in small annuli patients with no valve related mortality at one year - TCT oral presentation
-
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed...
-
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
-
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
-
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
-
Anteris Announces Results for the Second Quarter of 2025
-
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
-
Anteris Announces Results for the First Quarter of 2025
-
Anteris Technologies reaches clinical milestone: 100 patients treated with DurAVR® Transcatheter Heart Valve (THV)